Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Streptococcal B vaccine conjugate - GlaxoSmithKline

Next Previous
Drug Profile

Streptococcal B vaccine conjugate - GlaxoSmithKline

Alternative Names: CRM-glycoconjugate GBS vaccine; GBS maternal vaccine; GBS Trivalent Vaccine; GBS vaccine; GBS vaccine - GlaxoSmithKline; GBS vaccine - Intercell; GBS vaccine - Valneva; Group B Streptococcus vaccine - Intercell; Group B Streptococcus vaccine - Valneva; Trivalent PG vaccine - GlaxoSmithKline

Latest Information Update: 22 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell
  • Developer GlaxoSmithKline
  • Class Conjugate vaccines; Glycoconjugates; Polysaccharides; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Streptococcal infections

Most Recent Events

  • 10 Dec 2016 GlaxoSmithKline completes a phase-II clinical trials in Streptococcal infections (Prevention, In volunteers, In adults) in Belgium (IM) (NCT02690181)
  • 01 Mar 2016 Phase-II clinical trials in Streptococcal infections (Prevention, In volunteers, In adults) in Belgium (IM) (NCT02690181)
  • 01 Mar 2016 Novartis Vaccines completes a phase II trial in Streptococcal infections (Prevention, In neonates, In infants) in USA (NCT02046148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top